LABP
Landos Biopharma, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website landosbiopharma.com
- Employees(FY) 22
- ISIN US5150692011
Performance
+0.49%
1W
+4.41%
1M
+301.25%
3M
+458.96%
6M
+513.93%
YTD
+649.0%
1Y
Profile
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company has a strategic research collaboration with KU Leuven and University Hospitals Leuven to investigate the effects of NX-13 on epithelial cells with the inflammatory bowel disease. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
Technical Analysis of LABP 2024-05-10
Overview:
In analyzing the technical indicators for LABP over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive assessment of the stock's potential price movement. By examining these key factors, we aim to offer valuable insights and predictions for the next few days.
Trend Anal...
Recent News & Updates
- 2024-05-09 01:53
LABP Stock Earnings: Landos Biopharma Misses EPS for Q1 2024(Investorplace)
- 2024-04-29 20:38
AbbVie Inc. (NYSE:ABBV) Q1 2024 Earnings Call Transcript(Insidermonkey)
- 2024-03-25 01:27
- 2024-03-25 00:17
Why Is Landos Biopharma (LABP) Stock Up 168% Today?(Investorplace)
- 2024-03-24 21:25
- 2024-03-24 20:31
- 2024-03-24 20:05
AbbVie to buy immune drug developer Landos(Yahoo Finance)
- 2024-03-21 01:52
LABP Stock Earnings: Landos Biopharma Misses EPS for Q4 2023(Investorplace)
- 2024-03-20 20:00
- 2024-01-07 19:00
- 2023-11-20 19:00
- 2023-11-08 19:00
- 2023-10-22 20:00
- 2023-09-18 20:00
- 2023-09-13 20:00
- 2023-08-08 20:00
- 2023-05-31 04:15
- 2023-05-30 04:15
- 2023-05-25 04:05
Landos Biopharma Announces 1-for-10 Reverse Stock Split(Yahoo Finance)
- 2023-05-11 20:50
- 2023-05-11 20:00
- 2023-03-22 20:00
- 2023-02-28 04:00
- 2023-01-10 18:00
- 2023-01-04 18:05
- 2023-01-04 18:00
- 2022-11-09 19:00
- 2022-10-14 21:36
- 2022-09-05 19:00
- 2022-08-12 06:37
Page 1 of 3
previousnext